AdAlta Ltd

[On Demand]
Search General Info
Search Education
Search Partnering Companies
AdAlta is a clinical stage drug company using its proprietary i-body (single domain antibody) platform to discover and develop therapeutics for high unmet need diseases and drug targets that challenge traditional antibodies. Lead asset, AD-214 is in Phase I clinical trials and being developed for a range of fibrotic diseases and cancer. It has Orphan Drug Designation for Idiopathic Pulmonary Fibrosis. Our second asset is being developed in collaboration with GE Healthcare for molecular imaging in immuno-oncology. We aim to add a further collaboration and two more internal programs by the end of 2021.
Ticker:
1AD
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
AD-214
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO and Managing Director
AdAlta Pty Ltd.